Sientra Inc (SIEN), TESARO Inc (TSRO) and Clovis Oncology Inc (CLVS): Orbimed’s Top New Picks

Page 2 of 2

The last company on our list,  Clovis Oncology Inc (NASDAQ:CLVS) is also focused in finding cancer treatments. Orbimed added some 714,100 shares of the healthcare company valued at $39.99 million. The $2.7 billion researcher of the much anticipated CO-1686 (rociletinib) drug forms 0.38% of Orbimed’s portfolio value. In November last year, Clovis Oncology Inc (NASDAQ:CLVS) announced its partnership with  GlaxoSmithKline plc (ADR) (NYSE:GSK) in a clinical trial collaboration to study if CO-1686 can cure lung cancer patients when combined GSK’s Mekinist, which was approved last year. The company’s stock is up nearly 47.6% since then.

William Leland Edwards’ Palo Alto Investors and Christopher Medlock James’ Partner Fund Management increased their stakes by 23% and 36% to 2.1 million shares and 1.72 million shares respectively during the fourth quarter.

Disclosure: none

Page 2 of 2